Mesothelin x CD3 Bispecific Antibody(Integral Molecular)

N/A

Report date: 2026/03/19 17:14:53

Base Information

Drug NameMesothelin x CD3 Bispecific Antibody(Integral Molecular)
Drug Alias NameCT-95LNK-101LNK101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionCytotoxic T lymphocytes stimulantsAnti-CD3Anti-Mesothelin
TargetsT cell surface glycoprotein CD3Mesothelin
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisPancreatic Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesIntegral Molecular Inc
China Registration ClassN/A

Develop Information

Active CompaniesContext Therapeutics IncIntegral Molecular Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm MetastasisPancreatic Neoplasms +[7] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A